Compare SIGI & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIGI | PTCT |
|---|---|---|
| Founded | 1926 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 1996 | 2006 |
| Metric | SIGI | PTCT |
|---|---|---|
| Price | $87.12 | $68.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 17 |
| Target Price | ★ $85.80 | $80.65 |
| AVG Volume (30 Days) | 276.1K | ★ 775.7K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | 131.89 | ★ 264.48 |
| EPS | ★ 3.69 | 0.90 |
| Revenue | ★ $5,336,928,000.00 | $264,734,000.00 |
| Revenue This Year | $0.41 | N/A |
| Revenue Next Year | $4.81 | $17.70 |
| P/E Ratio | ★ $24.05 | $74.88 |
| Revenue Growth | 9.78 | ★ 36.19 |
| 52 Week Low | $72.78 | $57.74 |
| 52 Week High | $100.40 | $90.87 |
| Indicator | SIGI | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 44.07 |
| Support Level | $81.10 | $67.57 |
| Resistance Level | $91.48 | $69.02 |
| Average True Range (ATR) | 1.69 | 1.81 |
| MACD | -0.21 | -0.06 |
| Stochastic Oscillator | 16.17 | 42.85 |
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. Majority of revenue is gained from Standard Commercial Lines segment, which comprises of property and casualty insurance products and services provided in the standard marketplace to commercial enterprises, which are typically businesses, non-profit organizations, and local government agencies.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.